Contineum Therapeutics (CTNM) Enterprise Value (2023 - 2026)

Contineum Therapeutics' Enterprise Value history runs 4 years deep, the most recent figure standing at -$246.3 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 29.16% year-over-year to -$246.3 million in Q1 2026; TTM through Mar 2026 was -$246.3 million, a 29.16% decrease from a year earlier, with the FY2025 full-year figure at -$262.9 million, down 28.39% from the prior year.
• Enterprise Value advanced to -$246.3 million in Q1 2026 per CTNM's latest filing, from -$262.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$117.9 million in Q1 2024 and bottomed at -$262.9 million in Q4 2025.
• The 4-year median for Enterprise Value is -$197.7 million (2024), against an average of -$193.8 million.
• Across the five-year window, Enterprise Value slumped 63.56% in 2024 and gained 19.74% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$125.2 million in 2023, then slumped by 63.56% to -$204.8 million in 2024, then slipped by 28.39% to -$262.9 million in 2025, then rose by 6.3% to -$246.3 million in 2026.
• Per Business Quant, the three latest CTNM Enterprise Value figures stand at -$246.3 million (Q1 2026), -$262.9 million (Q4 2025), and -$182.4 million (Q3 2025).